Edition:
United Kingdom

Puma Biotechnology Inc (PBYI.OQ)

PBYI.OQ on NASDAQ Stock Exchange Global Select Market

52.00USD
20 Jul 2018
Change (% chg)

$-0.45 (-0.86%)
Prev Close
$52.45
Open
$52.20
Day's High
$52.75
Day's Low
$51.80
Volume
96,773
Avg. Vol
219,290
52-wk High
$136.90
52-wk Low
$47.10

Chart for

About

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous))... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $4,516.76
Shares Outstanding(Mil.): 37.21
Dividend: --
Yield (%): --

Financials

  PBYI.OQ Industry Sector
P/E (TTM): -- 85.33 32.76
EPS (TTM): -8.14 -- --
ROI: -224.57 2.22 14.61
ROE: -233.95 3.86 16.34

Puma Biotech gets EU panel nod for breast cancer drug

Puma Biotechnology Inc  on Friday won a key recommendation from a European Medicines Agency panel on its lead breast cancer drug, five months after the regulator recommended against approving it.

29 Jun 2018

Puma Biotech gets EU panel nod for breast cancer drug

June 29 Puma Biotechnology Inc on Friday won a key recommendation from a European Medicines Agency panel on its lead breast cancer drug, five months after the regulator recommended against approving it.

29 Jun 2018

Puma Biotech says Europe likely to approve breast cancer drug

Puma Biotechnology Inc said on Tuesday a committee of the European Medicines Agency was likely to give positive opinion on its breast cancer drug, five months after the regulator recommended against approving it.

26 Jun 2018

Puma Biotech says Europe likely to approve breast cancer drug

Puma Biotechnology Inc said on Tuesday a committee of the European Medicines Agency was likely to give positive opinion on its breast cancer drug, five months after the regulator recommended against approving it.

26 Jun 2018

UPDATE 1-Puma Biotech says Europe likely to approve breast cancer drug

June 26 Puma Biotechnology Inc said on Tuesday a committee of the European Medicines Agency was likely to give positive opinion on its breast cancer drug, five months after the regulator recommended against approving it.

26 Jun 2018

Puma Biotech says Europe likely to approve breast cancer drug

June 26 Puma Biotechnology Inc said on Tuesday a committee of the European Medicines Agency was likely to give positive opinion on its breast cancer drug, five months after the regulator recommended against approving it.

26 Jun 2018

Former Puma Biotech exec gets U.S. prison term for insider trading

BOSTON, June 20 A former Puma Biotechnology Inc executive was sentenced on Wednesday to 2-1/4 years in prison for trading on inside information ahead of announcements by the biopharmaceutical company about a breast cancer drug it was developing.

20 Jun 2018

BRIEF-Puma Biotechnology Q1 Loss Per Share $0.65

* PUMA BIOTECHNOLOGY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

09 May 2018

BRIEF-Puma Biotechnology And Pint Pharma Enter Licensing Agreement To Commercialize Nerlynx In Latin America

* PUMA BIOTECHNOLOGY AND PINT PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN LATIN AMERICA

03 Apr 2018

BRIEF-Puma Biotechnology ‍Nerlynx Included As Recommended Treatment Option In NCCN Clinical Practice Guidelines

* ‍NERLYNX INCLUDED AS RECOMMENDED TREATMENT OPTION IN NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY CENTRAL NERVOUS SYSTEM CANCERS

02 Apr 2018

Earnings vs. Estimates